Targeting oncogenic KRAS in non-small cell lung cancer with EGFR aptamer-conjugated multifunctional RNA nanoparticles.

ABSTRACT: KRAS mutations are one of the most common oncogenic driver mutations in human cancers, including non-small cell lung cancer (NSCLC), and have established roles in cancer pathogenesis and therapeutic resistance. The development of effective inhibitors of mutant KRAS represents a significant challenge. Three-way junction (3WJ)-based multi-functional RNA nanoparticles have the potential to serve as an effective in vivo siRNA delivery platform with the ability to enhance tumor targeting specificity and visualize biodistribution through an imaging moiety. Herein, we assembled novel EGFR_apt-3WJ-siKRAS^G12C mutation targeted nanoparticles to target EGFR-expressing human NSCLC harboring a KRAS^G12C mutation to silence

SUBMITTER: Yang L 

PROVIDER: S-EPMC10448464 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature